BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Amylyx prices newly approved ALS drug, Relyvrio
The wholesale acquisition cost for Amylyx Pharmaceuticals Inc.'s new U.S. FDA-approved amyotrophic lateral sclerosis (ALS) treatment, Relyvrio, has been set at about...

More in BioWorld

BioWorld MedTech

Cionic steps up with $12.4M series A for mobility augmentation device
Cionic Inc. doubled its funding to date with a $12.5 million series A round led by Bluerun Ventures. The cash infusion will support the manufacturing and delivery of the...

More in BioWorld MedTech

BioWorld Science

Damage in noncoding DNA linked to neurological disease
New research indicates faults in repairing DNA breaks that are caused by oxidative stress in the noncoding parts of the genome are directly involved in the development of...

More in BioWorld Science

BioWorld Asia

Abpro inks potential $1.75B deal with Celltrion for HER2+ cancer therapy
Abpro Corp. and Celltrion Healthcare Inc. entered a global partnership valued at up to $1.75 billion involving ABP-102, a bispecific antibody targeting HER2-positive...

More in BioWorld Asia

BioWorld Insider Podcast

BioWorld staff writer Lee Landenberger talks with James Lanthier, the CEO of Mindset Pharma, which is developing what it calls “next-generation” psychedelic medicines to treat neurological and psychiatric disorders.